Fig. 5
From: Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model
Ibrutinib aids doxil entry to hinder glioma progression. An intact blood–brain barrier limits doxil permeability through brain endothelial tight junction integrity and ABCB1 efflux activity. In the context of the blood-tumor barrier treated with ibrutinib, junctional expression is decreased, ABCB1 function is inhibited and doxil therapy entry is enhanced to delay glioma migration and growth for prolonged survival. Images created via Biorender